Stromal disrupting effects of nab-paclitaxel in pancreatic cancer

2013290 citationsJournal Articlehybrid Open Access

Authors

Rafael Álvarez · Centro Oncológico de Galicia

Mónica Musteanu · Spanish National Cancer Research Centre

Elena García-García · Spanish National Cancer Research Centre

Pedro P. López‐Casas · Spanish National Cancer Research Centre

Diego Megı́as · Spanish National Cancer Research Centre

Carmen Guerra · Spanish National Cancer Research Centre

Manuel Muñoz

Abstract

These data suggest that nab-paclitaxel and gemcitabine decreases CAF content inducing a marked alteration in cancer stroma that results in tumour softening. This regimen should be studied in patients with operable PDA.

Topics & Keywords

Pancreatic and Hepatic Oncology Research Cancer Cells and Metastasis Cancer Genomics and Diagnostics

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: British Journal of Cancer

Volume 109, Issue 4, pp. 926-933

DOI: 10.1038/bjc.2013.415

Field-Weighted Citation Impact: 14.85